Skip to main content

Advertisement

SpringerLink
Log in

Haematological cancer

Tabelecleucel is effective in EBV-positive lymphoproliferative disease

  • Research Highlight
  • Published:

From Nature Reviews Clinical Oncology

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

Original article

  • Mahadeo, K. M. et al. Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein–Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial. Lancet Oncol. https://doi.org/10.1016/S1470-2045(23)00649-6 (2024)

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Clinical Oncology http://www.nature.com/nrclinonc

    Diana Romero

Authors
  1. Diana Romero
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Diana Romero.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Romero, D. Tabelecleucel is effective in EBV-positive lymphoproliferative disease. Nat Rev Clin Oncol 21, 251 (2024). https://doi.org/10.1038/s41571-024-00873-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41571-024-00873-3

  • Springer Nature Limited

Search

Navigation